We have just released the latest update to the Open Targets Platform — 24.09.
Please note, this will be the last release of the year. We are working on major updates to the Platform web interface, which we will share with you in our March 2025 release (25.03). See you there!
Key highlights for this release:
This release integrates 17,853,184 evidence strings to build 8,155,988 target-disease associations between 28,327 diseases and 63,121 targets from the following 23 public resources:
- 3,040,055 genetic evidence from European Variation Archive (EVA)
- 781,213 genetic evidence from Open Targets Genetics
- 3,644 genetic evidence from Gene2Phenotype
- 34,456 genetic evidence from the Genomics England PanelApp
- 2,764 genetic evidence from ClinGen
- 6,271 genetic evidence from Orphanet
- 36,740 genetic evidence from Gene burden
- 21,726 genetic evidence from CRISPRBrain
- 4,602 genetic evidence from UniProt Literature
- 17,045 somatic evidence from European Variation Archive (EVA)
- 4,359 somatic evidence from intOGen
- 82,754 somatic evidence from the Cancer Gene Census
- 29,036 somatic evidence from Uniprot
- 652,859 drug evidence from ChEMBL
- 230,078 expression evidence from Expression Atlas
- 10,186 affected pathway evidence from Reactome
- 72,441 affected pathway evidence from SLAPenrich
- 378 affected pathway evidence from PROGENy
- 389 systems biology evidence from SysBio
- 1,300 somatic evidence from the Cancer Genome Interpreter
- 517 CRISPR-Cas9 (Cancer Cell Lines) evidence from Pacini et al. (2024)
- 1,156,920 mouse model evidence from IMPC
- 11,663,451 scientific literature evidence from co-occurrence mining in Europe PMC
Additionally, the Platform now allows users to explore data on 18,041 drugs.
For more details, read the 24.09 blog post.